PMID- 38495408
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240426
IS  - 2160-200X (Print)
IS  - 2160-200X (Electronic)
IS  - 2160-200X (Linking)
VI  - 14
IP  - 1
DP  - 2024
TI  - Retrospective study on the short-term efficacy of different doses of 
      Spironolactone in patients with heart failure of ischemic cardiomyopath and the 
      influence of ventricular remodeling markers.
PG  - 21-28
AB  - OBJECTIVE: To evaluate the impact of varying dosages of Spironolactone on the 
      short-term effectiveness and ventricular remodeling indicators in patients with 
      Heart Failure of Ischemic Cardiomyopathy (HFIC). METHODS: A cohort of 141 HFIC 
      patients, admitted to our hospital between October 2018 and February 2023, were 
      enrolled for this study. Alongside the standard treatment for Chronic Congestive 
      Heart Failure (CHF), these patients were randomly assigned to either a low-dose 
      (20 mg/d, N=70) or a high-dose (60 mg/d, N=71) Spironolactone group. After four 
      weeks, various parameters were assessed and compared within each group before and 
      after the treatment. These parameters included echocardiographic indices (LVEF, 
      LVESD, LVEDD, LVESV, and LVEDV), New York Heart Association (NYHA) cardiac 
      function classification, ventricular remodeling markers (hs-CRP, TNF-alpha, NT-pro 
      BNP, Gal-3, MMP-9, and TIMP-4), and the Six Minute Walk Distance (6MWD). RESULTS: 
      Both low-dose and high-dose Spironolactone significantly improved LVEF and 6MWD 
      in HFIC patients (P<0.05), as well as markedly reduced LVESD, LVEDD, LVESV, 
      LVEDV, and NYHA cardiac function grades (P<0.05). The high-dose group exhibited 
      the most pronounced improvements (P<0.05). High-dose Spironolactone was more 
      effective in improving the clinical and total effective rate compared to the 
      low-dose, significantly reducing treatment inefficacy (P<0.05). Both dosages 
      significantly increased serum potassium levels within normal ranges. They also 
      improved the expression of ventricular remodeling markers (hs-CRP, TNF-alpha, NT-pro 
      BNP, Gal-3, MMP-9, and TIMP-4) in HFIC patients, with the high-dose group showing 
      the most significant results (P<0.05). CONCLUSION: High-dose Spironolactone (60 
      mg/d) demonstrates superior efficacy over the low-dose (20 mg/d) in rapidly 
      diminishing ventricular remodeling damage and enhancing cardiac function and 
      clinical symptoms in HFIC patients over a short duration.
CI  - AJCD Copyright (c) 2024.
FAU - Xie, Li
AU  - Xie L
AD  - Department of Cardiology, The Second Affiliated Hospital, Army Medical University 
      (Third Military Medical University) Chongqing 400037, China.
FAU - Xiao, Han
AU  - Xiao H
AD  - Department of Cardiology, The Second Affiliated Hospital, Army Medical University 
      (Third Military Medical University) Chongqing 400037, China.
FAU - Zhao, Maoyu
AU  - Zhao M
AD  - Department of Cardiology, The Second Affiliated Hospital, Army Medical University 
      (Third Military Medical University) Chongqing 400037, China.
FAU - Tang, Si
AU  - Tang S
AD  - Department of Cardiology, The Second Affiliated Hospital, Army Medical University 
      (Third Military Medical University) Chongqing 400037, China.
FAU - Qiu, Youzhu
AU  - Qiu Y
AD  - Department of Cardiology, The Second Affiliated Hospital, Army Medical University 
      (Third Military Medical University) Chongqing 400037, China.
LA  - eng
PT  - Journal Article
DEP - 20240220
PL  - United States
TA  - Am J Cardiovasc Dis
JT  - American journal of cardiovascular disease
JID - 101569582
PMC - PMC10944353
OTO - NOTNLM
OT  - Heart failure of ischemic cardiomyopath
OT  - cardiac function
OT  - chronic congestive heart failure
OT  - renin angiotensin aldosterone system
OT  - spironolactone
OT  - ventricular remodeling
COIS- None.
EDAT- 2024/03/18 06:42
MHDA- 2024/03/18 06:43
PMCR- 2024/02/20
CRDT- 2024/03/18 04:20
PHST- 2023/11/05 00:00 [received]
PHST- 2024/01/24 00:00 [accepted]
PHST- 2024/03/18 06:43 [medline]
PHST- 2024/03/18 06:42 [pubmed]
PHST- 2024/03/18 04:20 [entrez]
PHST- 2024/02/20 00:00 [pmc-release]
AID - 10.62347/SYIX9692 [doi]
PST - epublish
SO  - Am J Cardiovasc Dis. 2024 Feb 20;14(1):21-28. doi: 10.62347/SYIX9692. eCollection 
      2024.